<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05000671</url>
  </required_header>
  <id_info>
    <org_study_id>GPHIP-0103</org_study_id>
    <nct_id>NCT05000671</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Effect of STC314 Injection Continuous Infusion in Subjects With Acute Respiratory Distress Syndrome</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Phase Ib Clinical Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Continuous Intravenous Infusion of STC314 Injection in Chinese Patients With Acute Respiratory Distress Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grand Medical Pty Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Grand Pharmaceutical (China) Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Grand Medical Pty Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Randomized, Double-blinded, Placebo-controlled Phase Ib Study to Evaluate the&#xD;
      Safety, Tolerability and Pharmacokinetics of STC314 Injection Administered as Continuous&#xD;
      Intravenous Infusion in Chinese Patients with ARDS (Acute Respiratory Distress Syndrome).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety of STC314 injection in patients with ARDS.</measure>
    <time_frame>Within 28 days after the start of treatment</time_frame>
    <description>The incidence of adverse event (AE) and serious adverse event (SAE);</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the safety of STC314 injection in patients with ARDS.</measure>
    <time_frame>Within 28 days after the start of treatment</time_frame>
    <description>Rates of Treatment Discontinuation Due to Adverse Events;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the pharmacokinetic of STC314 injection in patients with ARDS.</measure>
    <time_frame>Through 0 to144 hours after the start of treatment</time_frame>
    <description>maximum concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the pharmacokinetic of STC314 injection in patients with ARDS.</measure>
    <time_frame>Through 0 to144 hours after the start of treatment</time_frame>
    <description>area under the plasma concentration-time curve (AUC0-t, AUC0-inf)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the pharmacokinetic of STC314 injection in patients with ARDS.</measure>
    <time_frame>Through 0 to144 hours after the start of treatment</time_frame>
    <description>time to peak (Tmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the pharmacokinetic of STC314 injection in patients with ARDS.</measure>
    <time_frame>Through 0 to144 hours after the start of treatment</time_frame>
    <description>elimination half Decay (t1/2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the pharmacokinetic of STC314 injection in patients with ARDS.</measure>
    <time_frame>Through 0 to144 hours after the start of treatment</time_frame>
    <description>elimination rate constant(Kel)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the pharmacokinetic of STC314 injection in patients with ARDS.</measure>
    <time_frame>Through 0 to144 hours after the start of treatment</time_frame>
    <description>clearance (CL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of STC314 injection in patients with ARDS.</measure>
    <time_frame>Within 28 days after the start of treatment</time_frame>
    <description>Changes of the value of blood lactate from baseline after dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of STC314 injection in patients with ARDS.</measure>
    <time_frame>Within 28 days after the start of treatment</time_frame>
    <description>Change of Oxygenation Index (PaO2/FiO2) from baseline after dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of STC314 injection in patients with ARDS.</measure>
    <time_frame>Within 28 days after the start of treatment</time_frame>
    <description>Change of Murray Lung Injury Score from baseline.(range 0-4, higher score means more severe lung injury)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of STC314 injection in patients with ARDS.</measure>
    <time_frame>Within 28 days after the start of treatment</time_frame>
    <description>Change of the value of serum creatinine from baseline after dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of STC314 injection in patients with ARDS.</measure>
    <time_frame>Within 28 days after the start of treatment</time_frame>
    <description>Change of the value of bilirubin from baseline after dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of STC314 injection in patients with ARDS.</measure>
    <time_frame>Within 28 days after the start of treatment</time_frame>
    <description>Change of the value of Alanine Transaminase(ALT) from baseline after dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of STC314 injection in patients with ARDS.</measure>
    <time_frame>Within 28 days after the start of treatment</time_frame>
    <description>Change of Sequential Organ Failure Assessment score from baseline after dosing.(range 0-4, higher score means a worse prognosis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of STC314 injection in patients with ARDS.</measure>
    <time_frame>Within 28 days after the start of treatment</time_frame>
    <description>all-cause mortality within 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of STC314 injection in patients with ARDS.</measure>
    <time_frame>Within 28 days after the start of treatment</time_frame>
    <description>Ventilator-free survival time within 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of STC314 injection in patients with ARDS.</measure>
    <time_frame>Within 28 days after the start of treatment</time_frame>
    <description>Hospitalization time within 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of STC314 injection in patients with ARDS.</measure>
    <time_frame>Within 28 days after the start of treatment</time_frame>
    <description>length of ICU stay within 28 days</description>
  </secondary_outcome>
  <other_outcome>
    <measure>As an exploratory objective, the change in biomarkers from baseline following STC314 injection treatment in subjects with Acute Respiratory Distress Syndrome will be evaluated.</measure>
    <time_frame>Through 0 to144 hours after the start of treatment</time_frame>
    <description>Change of the level of Histone in plasma after dosing</description>
  </other_outcome>
  <other_outcome>
    <measure>As an exploratory objective, the change in biomarkers from baseline following STC314 injection treatment in subjects with Acute Respiratory Distress Syndrome will be evaluated.</measure>
    <time_frame>Through 0 to144 hours after the start of treatment</time_frame>
    <description>Change of the level of Neutrophil extracellular traps(NETs)-related variables in plasma after dosing [myelinated Oxidase (MPO), citrullinated histone H3 (CitH3), circular free DNA (cfDNA)]</description>
  </other_outcome>
  <other_outcome>
    <measure>As an exploratory objective, the change in biomarkers from baseline following STC314 injection treatment in subjects with Acute Respiratory Distress Syndrome will be evaluated.</measure>
    <time_frame>Through 0 to144 hours after the start of treatment</time_frame>
    <description>Change of the level of inflammatory factor interleukin-6 (IL-6) after dosing</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: STC314/Placebo injection Continuous infusion at rate 58.3mg/hr up to 3 days (72 hours) N=8(Randomization-STC314/Placebo injection=3:1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: STC314/Placebo injection Continuous infusion at rate 87.5mg/hr up to 3 days (72 hours) N=8(Randomization-STC314/Placebo injection=3:1)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STC314 injection or Placebo(rate=58.3 mg/hr)</intervention_name>
    <description>To receive continuous infusion of STC314/Placebo injection at rate 58.3mg/hr up to 3 days (72hours). Also to receive appropriate standard of care.</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STC314 injection or Placebo(rate=87.5 mg/hr)</intervention_name>
    <description>To receive continuous infusion of STC314/Placebo injection at rate 87.5mg/hr up to 3 days (72hours). Also to receive appropriate standard of care.</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 ≤ age ≤ 70 years, male or female;&#xD;
&#xD;
          2. Voluntarily participate in the study and sign the informed consent form;&#xD;
&#xD;
          3. Diagnosis of ARDS for no more than 48 hours (starting at the time of diagnosis&#xD;
             recorded in the medical record)；&#xD;
&#xD;
          4. The following 2012 Berlin definition criteria for mild to moderate ARDS were met:&#xD;
&#xD;
               1. From known clinical impairment and new or worsening of respiratory symptoms to&#xD;
                  fulfillment of diagnostic criteria is less than 7 days(inclusive).&#xD;
&#xD;
               2. Chest imaging suggests bilateral infiltrates. The effusion, lobar/atelectasis, or&#xD;
                  nodules cannot completely explain the phenomenon.&#xD;
&#xD;
               3. Respiratory failure cannot be completely explained by heart failure or fluid&#xD;
                  overload;&#xD;
&#xD;
               4. When PEEP or CPAP ≥5 cm H2O, 100 mmHg≤PaO2/FiO2≤300 mmHg;&#xD;
&#xD;
          5. Male subjects agree to use an effective contraceptive method from the start of the&#xD;
             study until 7 days after the end of treatment; Female subjects of childbearing age&#xD;
             agree to use an effective contraceptive method from the start of the study until 3&#xD;
             months after the end of treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Positive serum pregnancy test before dosing for women of childbearing potential,&#xD;
             pregnant women, or lactating women;&#xD;
&#xD;
          2. Terminal phase of chronic disease with an expected survival of no more than 6 months;&#xD;
&#xD;
          3. Combined with one of the following chronic organ damage or immunosuppressive diseases:&#xD;
&#xD;
               1. Heart: New York Heart Association functional class IV;&#xD;
&#xD;
               2. Lung: severe lung disease, including pulmonary hypertension, oxygen therapy or&#xD;
                  ventilator dependence for more than one month cumulatively within the first six&#xD;
                  months of screening, end-stage lung disease, or severe exercise limitation caused&#xD;
                  by chest wall malformations;&#xD;
&#xD;
               3. Kidney: ongoing long-term dialysis treatment;&#xD;
&#xD;
               4. Liver: biopsy confirmed cirrhosis and portal hypertension, or previous upper&#xD;
                  gastrointestinal bleeding caused by portal hypertension; Liver failure, hepatic&#xD;
                  encephalopathy, or hepatic coma;&#xD;
&#xD;
               5. Immunosuppression: with lymphoma, leukemia or acquired immunodeficiency; Received&#xD;
                  anti-tumor chemotherapy in the last 3 months, or ongoing immunosuppressive&#xD;
                  therapy due to organ transplantation, immune diseases, etc.; Has undergone&#xD;
                  allogeneic bone marrow transplantation or hematopoietic stem cell&#xD;
                  transplantation; Steroid hormone therapy in the last 3 months (equivalent to &gt;&#xD;
                  0.5 mg/kg/day prednisone continued 1 month);&#xD;
&#xD;
          4. History of one of the following within 4 weeks prior to screening:&#xD;
&#xD;
               1. Acute pulmonary embolism;&#xD;
&#xD;
               2. Cardiac arrest;&#xD;
&#xD;
               3. Acute myocardial infarction;&#xD;
&#xD;
          5. eGFR &lt; 60 mL/min/BSA (calculated using CG formula);&#xD;
&#xD;
          6. ALT &gt; 5 x ULN, or total bilirubin &gt; 2 x ULN;&#xD;
&#xD;
          7. Severe anemia (hemoglobin &lt; 7.0 g/dL);&#xD;
&#xD;
          8. Absolute neutrophil count &lt; 1500/μL;&#xD;
&#xD;
          9. Platelet count &lt; 50,000/μL;&#xD;
&#xD;
         10. aPTT &gt; 1.5 × ULN;&#xD;
&#xD;
         11. Active bleeding that cannot be effectively controlled;&#xD;
&#xD;
         12. The subject required therapeutic doses of heparin or was taking anticoagulants;&#xD;
&#xD;
         13. ARDS caused by direct lung injury due to physical or chemical causes;&#xD;
&#xD;
         14. Severe or greater burns: the overall surface area of burns exceeds 30% or the III&#xD;
             degree burn area exceeds 10%; or the total area is less than 30%, but the general&#xD;
             condition is severe or has shock, combined injury, respiratory tract burn;&#xD;
&#xD;
         15. Allergic to the active ingredients or excipients of the study drug;&#xD;
&#xD;
         16. Subjects have participated in other clinical studies (other than those who have not&#xD;
             received intervention) or are participating in other experimental treatments within 1&#xD;
             month prior to screening;&#xD;
&#xD;
         17. In the opinion of the investigator, the subject could not benefit from the study or&#xD;
             was not suitable for participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>James Pang, PhD</last_name>
    <phone>+61 466555916</phone>
    <email>jpang@grandpharma.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Fourth Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhenjie Hu, MD</last_name>
      <email>syicu@vip.sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuhan Jinyintan Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wenjuan Wu, MD</last_name>
      <email>1346801465@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuhan Union Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shiying Yuan, MD</last_name>
      <email>yuan_shiying@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Pinhua Pan, MD</last_name>
      <email>pinhuapan668@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongda Hospital Southeast University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Haibo Qiu, MD</last_name>
      <email>haiboq2000@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2021</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

